BR0312312A - Composto, formulação farmacêutica, uso de um composto, processo para a preparação de compostos, e, intermediários - Google Patents
Composto, formulação farmacêutica, uso de um composto, processo para a preparação de compostos, e, intermediáriosInfo
- Publication number
- BR0312312A BR0312312A BR0312312-0A BR0312312A BR0312312A BR 0312312 A BR0312312 A BR 0312312A BR 0312312 A BR0312312 A BR 0312312A BR 0312312 A BR0312312 A BR 0312312A
- Authority
- BR
- Brazil
- Prior art keywords
- group
- optionally substituted
- compound
- fluorine
- alkyl group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Quinoline Compounds (AREA)
Abstract
"COMPOSTO, FORMULAçãO FARMACêUTICA, USO DE UM COMPOSTO, PROCESSO PARA A PREPARAçãO DE COMPOSTOS, E, INTERMEDIáRIOS". A presente invenção fornece compostos de fórmula (I), em que R^ 1^ representa um grupo alcóxi C~ 1-4~ opcionalmente substituído com um ou mais flúor ou um grupo alquila C~ 1-4~ opcionalmente substituído com um ou mais flúor; n representa O ou 1; R^ 2^ representa um grupo alquila C~ 1-4~ opcionalmente substituído com um ou mais flúor ou um grupo alcóxi C~ 1-4~ opcionalmente substituído com um ou mais flúor; m representa O ou 1; R^ 3^ representa H ou um grupo alquila C~ 1-4~; L^ 1^ representa uma cadeia de alquileno (CH~ 2~)~ r~, em que r representa 2 ou 3, ou L^ 1^ representa um grupo cicloexila em que os dois nitrogênios que carregam R^ 3^ e R^ 4^, respectivamente, são ligados ao grupo cicloexila ou através das posições 1,3 ou 1,4 do grupo cicloexila, ou L^ 1^ representa um grupo ciclopentila em que os dois nitrogênios carregando R^ 3^ e R^ 4^, respectivamente, são ligados ao grupo ciclopentila através da posição 1,3 do grupo ciclopentila e, adicionalmente, quando R^ 5^ representa 9,10-metanoantracen-9(10H)-ila, o grupo -L^ 1^-N(R^ 4^)- junto representa um anel piperidila que é ligado a L^ 2^ através do nitrogênio da piperidinila, e a N-R^ 3^ através da posição 4 do anel piperidinila, com a condição de que, quando R^ 5^ representa 9,10-metanoantracen-9(10H)-ila então r é apenas 2; R^ 4^ representa H ou um grupo alquila C~ 1-4~ opcionalmente substituído com um ou mais do seguinte: um grupo arila ou um grupo heteroarila; L^ 2^ representa uma ligação ou uma cadeia de alquileno (CH~ 2~), em que s representa 1, 2 ou 3 em que a cadeia de alquileno é opcionalmente substituída com um ou mais do seguinte: um gmpo alquila C~ 1-4~, fenila ou heteroarila; W representa arila, um grupo heterocíclico ou um grupo cicloalquila C~ 3-8~, o qual é opcionalmente fundido a uma fenila ou a um grupo heteroarila, assim como seus isómeros ópticos ou racematos, bem como seus sais farmaceuticamente aceitáveis; com as condições, processos para preparar tais compostos, seu uso no tratamento de obesidade, distúrbios psiquiátricos, distúrbios cognitivos, distúrbios da memória, esquizofrenia, epilepsia, e condições relacionadas, e distúrbios neurológicos tais como demência, esclerose múltipla, Mal de Parkinson, coréia de Huntington, e Mal de Alzheimer, e distúrbios relacionados à dor, e a composições farmacêuticas contendo-os.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0202134A SE0202134D0 (sv) | 2002-07-08 | 2002-07-08 | Therapeutic agents |
PCT/GB2003/002884 WO2004004726A1 (en) | 2002-07-08 | 2003-07-04 | Mchir antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0312312A true BR0312312A (pt) | 2005-04-12 |
Family
ID=20288471
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0312312-0A BR0312312A (pt) | 2002-07-08 | 2003-07-04 | Composto, formulação farmacêutica, uso de um composto, processo para a preparação de compostos, e, intermediários |
Country Status (19)
Country | Link |
---|---|
US (1) | US20060247439A1 (pt) |
EP (1) | EP1528924A1 (pt) |
JP (1) | JP2006501186A (pt) |
CN (1) | CN1665502A (pt) |
AR (1) | AR040476A1 (pt) |
AU (1) | AU2003281194A1 (pt) |
BR (1) | BR0312312A (pt) |
CA (1) | CA2491835A1 (pt) |
CO (1) | CO5680403A2 (pt) |
IL (1) | IL165841A0 (pt) |
IS (1) | IS7653A (pt) |
MX (1) | MXPA05000336A (pt) |
NO (1) | NO20045528L (pt) |
PL (1) | PL374674A1 (pt) |
RU (1) | RU2004138079A (pt) |
SE (1) | SE0202134D0 (pt) |
TW (1) | TW200412957A (pt) |
WO (1) | WO2004004726A1 (pt) |
ZA (1) | ZA200500030B (pt) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1464335A3 (en) * | 2003-03-31 | 2007-05-09 | Taisho Pharmaceutical Co. Ltd. | Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist |
CN100451004C (zh) * | 2003-03-31 | 2009-01-14 | 大正制药株式会社 | 嘧啶衍生物 |
GB0400193D0 (en) * | 2004-01-07 | 2004-02-11 | Astrazeneca Ab | Therapeutic agents |
JP2007517868A (ja) * | 2004-01-07 | 2007-07-05 | アストラゼネカ アクチボラグ | 治療薬i |
RU2373197C2 (ru) * | 2004-03-30 | 2009-11-20 | Тайсо Фармасьютикал Ко., Лтд. | Пиримидиновые производные, обладающие активностью в отношении мсн |
WO2006015279A1 (en) * | 2004-07-28 | 2006-02-09 | Neurogen Corporation | Heterocyclic diamine compounds as ligands of the melanin concentrating hormone receptor useful for the treatment of obesity, diabetes, eating and sexual disorders |
WO2006035967A1 (en) * | 2004-09-30 | 2006-04-06 | Taisho Pharmaceutical Co., Ltd. | Pyridine derivatives and their use as medicaments for treating diseases related to mch receptor |
WO2006066174A1 (en) * | 2004-12-17 | 2006-06-22 | Eli Lilly And Company | Thiazolopyridinone derivates as mch receptor antagonists |
EP1978804B1 (en) * | 2006-01-25 | 2014-07-30 | Merck Sharp & Dohme Corp. | Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
FR2902100A1 (fr) * | 2006-06-13 | 2007-12-14 | Sanofi Aventis Sa | Molecules duales contenant un derive peroxydique, leur synthese et leurs applications en therapeutique |
CN101516852B (zh) * | 2006-09-28 | 2011-11-16 | 弗·哈夫曼-拉罗切有限公司 | 具有5-ht结合特性的喹啉衍生物 |
AU2009307884B2 (en) | 2008-10-22 | 2014-07-31 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US8329914B2 (en) | 2008-10-31 | 2012-12-11 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
SA110310332B1 (ar) | 2009-05-01 | 2013-12-10 | Astrazeneca Ab | مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل ) |
SG181498A1 (en) | 2009-12-04 | 2012-07-30 | Sunovion Pharmaceuticals Inc | Multicyclic compounds and methods of use thereof |
WO2011106273A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
AU2011275547B2 (en) | 2010-07-06 | 2015-10-29 | Astrazeneca Ab | Therapeutic agents 976 |
US8796258B2 (en) | 2011-02-25 | 2014-08-05 | Merck Sharp & Dohme Corp. | Cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
UY34194A (es) | 2011-07-15 | 2013-02-28 | Astrazeneca Ab | ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad? |
US20140045746A1 (en) | 2012-08-02 | 2014-02-13 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
JP2016516004A (ja) | 2013-02-22 | 2016-06-02 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 抗糖尿病二環式化合物 |
EP2970119B1 (en) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
WO2018023072A2 (en) | 2016-07-29 | 2018-02-01 | Sunovion Pharmaceuticals, Inc. | Compounds and compositions and uses thereof |
EP3490607A4 (en) | 2016-07-29 | 2020-04-08 | Sunovion Pharmaceuticals Inc. | COMPOUNDS AND COMPOSITIONS, AND USES THEREOF |
EP3551176A4 (en) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | ANTIDIABETIC HETEROCYCLIC COMPOUNDS |
EP3558298A4 (en) | 2016-12-20 | 2020-08-05 | Merck Sharp & Dohme Corp. | ANTIDIABETIC SPIROCHROMAN COMPOUNDS |
ES2968227T3 (es) * | 2016-12-23 | 2024-05-08 | Aquinnah Pharmaceuticals Inc | Compuestos, composiciones y procedimientos de uso |
EP3582815A1 (en) | 2017-02-16 | 2019-12-25 | Sunovion Pharmaceuticals Inc. | Methods of treating schizophrenia |
JP7191085B2 (ja) | 2017-08-02 | 2022-12-16 | サノビオン ファーマシューティカルズ インク | イソクロマン化合物およびその使用 |
US10815249B2 (en) | 2018-02-16 | 2020-10-27 | Sunovion Pharmaceuticals Inc. | Salts, crystal forms, and production methods thereof |
MX2021010880A (es) | 2019-03-14 | 2022-01-18 | Sunovion Pharmaceuticals Inc | Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas. |
CN115734785A (zh) | 2020-04-14 | 2023-03-03 | 桑诺维恩药品公司 | (S)-(4,5-二氢-7H-噻吩并[2,3-c]吡喃-7-基)-N-甲基甲胺用于治疗神经和精神方面的病症 |
US20240217951A1 (en) | 2022-09-23 | 2024-07-04 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
US20240228469A1 (en) | 2022-09-23 | 2024-07-11 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
US20240239767A1 (en) | 2022-12-16 | 2024-07-18 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3020283A (en) * | 1958-10-20 | 1962-02-06 | Abbott Lab | Bis-lepidines |
JPH05507702A (ja) * | 1990-05-30 | 1993-11-04 | アメリカン・ホーム・プロダクツ・コーポレイション | 置換アリールスルホンアミド類およびベンズアミド類 |
ZA974147B (en) * | 1996-05-14 | 1997-11-14 | Novo Nordisk As | Somatostatin agonists and antagonists. |
EP0973513A4 (en) * | 1996-10-23 | 2003-03-19 | Zymogenetics Inc | COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH BONE DEFICIT |
KR20010043131A (ko) * | 1998-04-29 | 2001-05-25 | 피터 기딩스 | Mrs 억제제 및 살균제로서 사용되는 퀴놀론 |
US6489344B1 (en) * | 1998-06-19 | 2002-12-03 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
ATE479429T1 (de) * | 2000-04-28 | 2010-09-15 | Takeda Pharmaceutical | Antagonisten des melanin-konzentrierenden hormons |
CA2433090A1 (en) * | 2000-12-27 | 2002-07-04 | Kyowa Hakko Kogyo Co., Ltd. | Dipeptidyl peptidase iv inhibitor |
EP1359915A4 (en) * | 2001-01-26 | 2004-07-21 | Smithkline Beecham | UROTENSIN-II RECEPTOR ANTAGONISTS |
-
2002
- 2002-07-08 SE SE0202134A patent/SE0202134D0/xx unknown
-
2003
- 2003-07-03 TW TW092118207A patent/TW200412957A/zh unknown
- 2003-07-04 CN CN038160749A patent/CN1665502A/zh active Pending
- 2003-07-04 BR BR0312312-0A patent/BR0312312A/pt not_active IP Right Cessation
- 2003-07-04 MX MXPA05000336A patent/MXPA05000336A/es not_active Application Discontinuation
- 2003-07-04 US US10/520,372 patent/US20060247439A1/en not_active Abandoned
- 2003-07-04 PL PL03374674A patent/PL374674A1/xx not_active Application Discontinuation
- 2003-07-04 EP EP03740771A patent/EP1528924A1/en not_active Withdrawn
- 2003-07-04 RU RU2004138079/04A patent/RU2004138079A/ru not_active Application Discontinuation
- 2003-07-04 JP JP2004518963A patent/JP2006501186A/ja active Pending
- 2003-07-04 WO PCT/GB2003/002884 patent/WO2004004726A1/en active Application Filing
- 2003-07-04 CA CA002491835A patent/CA2491835A1/en not_active Abandoned
- 2003-07-04 AU AU2003281194A patent/AU2003281194A1/en not_active Abandoned
- 2003-07-08 AR AR20030102464A patent/AR040476A1/es unknown
-
2004
- 2004-12-16 IL IL16584104A patent/IL165841A0/xx unknown
- 2004-12-17 NO NO20045528A patent/NO20045528L/no unknown
-
2005
- 2005-01-03 ZA ZA200500030A patent/ZA200500030B/en unknown
- 2005-01-19 IS IS7653A patent/IS7653A/is unknown
- 2005-01-28 CO CO05007427A patent/CO5680403A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
ZA200500030B (en) | 2005-11-11 |
IL165841A0 (en) | 2006-01-15 |
RU2004138079A (ru) | 2005-08-10 |
AU2003281194A1 (en) | 2004-01-23 |
IS7653A (is) | 2005-01-19 |
PL374674A1 (en) | 2005-10-31 |
TW200412957A (en) | 2004-08-01 |
CA2491835A1 (en) | 2004-01-15 |
WO2004004726A1 (en) | 2004-01-15 |
MXPA05000336A (es) | 2005-03-31 |
CO5680403A2 (es) | 2006-09-29 |
NO20045528L (no) | 2005-04-04 |
SE0202134D0 (sv) | 2002-07-08 |
US20060247439A1 (en) | 2006-11-02 |
EP1528924A1 (en) | 2005-05-11 |
CN1665502A (zh) | 2005-09-07 |
JP2006501186A (ja) | 2006-01-12 |
AR040476A1 (es) | 2005-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0312312A (pt) | Composto, formulação farmacêutica, uso de um composto, processo para a preparação de compostos, e, intermediários | |
AR038044A1 (es) | Compuesto derivado de pirazina, composicion farmaceutica, su uso en la fabricacion de un medicamento, proceso para su preparacion y compuesto intermediario en dicho proceso. | |
EA200500342A1 (ru) | Гетероциклические замещённые пиперазины для лечения шизофрении | |
PH12016502231A1 (en) | Indolin-2-one or pyrrolo-pyridin-2-one derivatives | |
AR017182A1 (es) | Compuestos de aminotiazol, inhibidores de las kinasas dependientes de ciclinas y las composiciones farmaceuticas que los contienen. | |
AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
AR069510A1 (es) | Arilo y heteroarilo imidazo[1,5-a]pirazinas fusionadas como inhibidores de la fosfodiesterasa 10 | |
AR084457A1 (es) | Derivados de biciclo[3,2,1]octilamida | |
AR038419A1 (es) | Derivados de piridina y quinolina | |
AR038045A1 (es) | Agentes terapeuticos | |
EA200500018A1 (ru) | Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения | |
BR0212760A (pt) | Compostos quìmicos | |
BRPI0110955B8 (pt) | derivados de tropano composição farmacêutica, uso dos mesmos na fabricação de um medicamento bem como processo para a preparação dos mesmos. | |
BRPI0614168A2 (pt) | Composto ou um sal, hidrato, solvato, isoforma, tautômero, isômero óptico farmaceuticamente aceitável ou uma combinação dos mesmos, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psquiátricos, uso de um composto, e, processo para a preparação de um composto | |
BRPI0308696B8 (pt) | composto derivado de quinolina, seu processo de preparação, sua composição farmacêutica e seus usos | |
UY28374A1 (es) | Agentes terapéuticos | |
AR077960A1 (es) | Derivados de benzamida n-sustituidos como inhibidores del transportador de glicina 1 (glyt-1) | |
AR070885A1 (es) | Compuestos de azaindol para el tratamiento de trastornos del sistema nervioso central | |
AR075160A1 (es) | Derivados de aril y/o heteroaril piperidinas sustituidas, medicamentos que las contienen, proceso para prepararlas y uso de las mismas para el tratamiento de trastornos neurologicos y neuropsiquiatricos. | |
ES2676198T3 (es) | Derivados amino-quinoxalina para el tratamiento de enfermedades neurodegenerativas | |
AR016644A1 (es) | Compuestos de 2-aminopiridinas con sustituyentes alcoxi ramificados, composicion farmaceutica y uso para la manufactura de medicamentos | |
BR0308765A (pt) | Compostos (4,2-dissubstituìdo-tiazol-5-il)amina como inibidores de pde7 | |
AR044579A1 (es) | Antagonistas de nmda/ nr2b nonaril - heterociclicos n- sustituidos | |
ES2094742T3 (es) | Aminocarbonilcarbamatos relacionados con fisostigmina, un procedimiento para su preparacion y su uso como medicamentos. | |
EA200501148A1 (ru) | Пиридилоксиметильные и бензизоксазольные азабициклические производные |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 4A, 5A,6A E 7A ANUIDADES |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2064 DE 27/07/2010. |